Literature DB >> 10805816

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.

C Wahlestedt1, P Salmi, L Good, J Kela, T Johnsson, T Hökfelt, C Broberger, F Porreca, J Lai, K Ren, M Ossipov, A Koshkin, N Jakobsen, J Skouv, H Oerum, M H Jacobsen, J Wengel.   

Abstract

Insufficient efficacy and/or specificity of antisense oligonucleotides limit their in vivo usefulness. We demonstrate here that a high-affinity DNA analog, locked nucleic acid (LNA), confers several desired properties to antisense agents. Unlike DNA, LNA/DNA copolymers were not degraded readily in blood serum and cell extracts. However, like DNA, the LNA/DNA copolymers were capable of activating RNase H, an important antisense mechanism of action. In contrast to phosphorothioate-containing oligonucleotides, isosequential LNA analogs did not cause detectable toxic reactions in rat brain. LNA/DNA copolymers exhibited potent antisense activity on assay systems as disparate as a G-protein-coupled receptor in living rat brain and an Escherichia coli reporter gene. LNA-containing oligonucleotides will likely be useful for many antisense applications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805816      PMCID: PMC25880          DOI: 10.1073/pnas.97.10.5633

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Keeping the biotechnology of antisense in context.

Authors:  C A Stein
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

2.  Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat.

Authors:  Michael H Ossipov; Carl J Kovelowski; Michael L Nichols; Victor J Hruby; Frank Porreca
Journal:  Pain       Date:  1995-09       Impact factor: 6.961

Review 3.  Antisense therapeutics.

Authors:  S Agrawal; Q Zhao
Journal:  Curr Opin Chem Biol       Date:  1998-08       Impact factor: 8.822

Review 4.  A biosynthetic approach for the incorporation of unnatural amino acids into proteins.

Authors:  J S Thorson; V W Cornish; J E Barrett; S T Cload; T Yano; P G Schultz
Journal:  Methods Mol Biol       Date:  1998

5.  Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects.

Authors:  W Zhou; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  1998-11-17       Impact factor: 2.823

Review 6.  A good antisense molecule is hard to find.

Authors:  A D Branch
Journal:  Trends Biochem Sci       Date:  1998-02       Impact factor: 13.807

7.  Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line.

Authors:  K A Markey; H Kondo; L Shenkman; M Goldstein
Journal:  Mol Pharmacol       Date:  1980-01       Impact factor: 4.436

Review 8.  Antisense oligonucleotide strategies in neuropharmacology.

Authors:  C Wahlestedt
Journal:  Trends Pharmacol Sci       Date:  1994-02       Impact factor: 14.819

9.  Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor.

Authors:  K M Standifer; C C Chien; C Wahlestedt; G P Brown; G W Pasternak
Journal:  Neuron       Date:  1994-04       Impact factor: 17.173

10.  Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.

Authors:  E J Bilsky; R N Bernstein; V J Hruby; R B Rothman; J Lai; F Porreca
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

View more
  174 in total

Review 1.  Target discovery and validation in the post-genomic era.

Authors:  Steven P Butcher
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

2.  Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.

Authors:  Dwaine A Braasch; Yinghui Liu; David R Corey
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

3.  Influenza A virus-generated small RNAs regulate the switch from transcription to replication.

Authors:  Jasmine T Perez; Andrew Varble; Ravi Sachidanandam; Ivan Zlatev; Muthiah Manoharan; Adolfo García-Sastre; Benjamin R tenOever
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

4.  RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Authors:  Steffen Schubert; Deniz C Gül; Hans-Peter Grunert; Heinz Zeichhardt; Volker A Erdmann; Jens Kurreck
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

5.  Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA.

Authors:  Kirsten M L Hertoghs; Jonathan H Ellis; Ian R Catchpole
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

6.  LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1.

Authors:  Fabien Darfeuille; Jens Bo Hansen; Henrik Orum; Carmelo Di Primo; Jean-Jacques Toulmé
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

7.  Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays.

Authors:  Daniel A Di Giusto; Garry C King
Journal:  Nucleic Acids Res       Date:  2004-02-18       Impact factor: 16.971

Review 8.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 9.  Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.

Authors:  Seyed Mohammad Ali Hosseini Rad; Lida Langroudi; Fatemeh Kouhkan; Laleh Yazdani; Alireza Nouri Koupaee; Sara Asgharpour; Zahra Shojaei; Taravat Bamdad; Ehsan Arefian
Journal:  Tumour Biol       Date:  2015-04-04

Review 10.  The role of miRNAs in cardiovascular disease risk factors.

Authors:  Joy N Jones Buie; Andrew J Goodwin; James A Cook; Perry V Halushka; Hongkuan Fan
Journal:  Atherosclerosis       Date:  2016-09-22       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.